Work

KEYNOTE-199 cohorts 4 and 5: Pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC)

Year: 2020

Type: article

Source: European Urology Open Science

DOI: 10.1016/s2666-1683(20)33171-2

Authors: R. McDermott, J.N. Graff, E.S. Antonarakis, C.J. Hoimes, S.T. Tagawa, C. Hwang, D. Kilari, A.J.T. Tije, A. Omlin, U.N. Vaishampayan, A. Elliott, H. Wu, J. Kim, C. Schloss, J.S. De Bono

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,800

OpenAlex ID: W3042225930

FWCI: 0.282

Cites:

Cited by: 2

Related to: 10